Scholarlink

<p>Functional bowel disorders (FBDs) are characterized by chronic abdominal discomfort, altered bowel habits, and bloating, impairing quality of life. Current treatments, including dietary interventions and laxatives, have limited effectiveness and raise safety concerns. Although probiotic-based interventions have gained attention, their mechanisms remain poorly understood. This randomized, double-blind, placebo-controlled pilot trial tested the heat-treated postbiotic <i>Lacticaseibacillus rhamnosus</i> IDCC 3201 (RHT) over an&#xa0;8-week period in patients with FBDs (RHT, <i>n</i> = 19; placebo, <i>n</i> = 15). Outcomes were measured using the IBS Symptom Severity Scale (IBS-SSS) and IBS Quality of Life (IBS-QOL) questionnaire. Results suggested that the RHT group showed reductions in IBS-SSS scores, alongside improvements in IBS-QOL and bowel activity across physical and psychosocial domains. Gut microbiota profiling revealed decreased <i>Klebsiella pneumoniae</i> and increased beneficial taxa, including <i>Fusicatenibacter saccharivorans</i> and <i>Bacteroides caccae</i>. Metabolomics analysis revealed progressive alterations in the RHT group, with clear distinction from baseline by week 8. Amino acid metabolism-related metabolites increased, whereas inflammation-associated eicosanoids decreased. These findings suggest that RHT alleviates FBD symptoms and improves quality of life by modulating gut microbiota and fecal metabolome, supporting its potential as a postbiotic-based therapeutic strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of heat-treated postbiotic Lacticaseibacillus rhamnosus in patients with functional bowel disorders: a randomized, double-blind, placebo-controlled clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月2日

查看全文
  • Donggyu Kim,
  • Won Yeong Bang,
  • Young Hoon Jung,
  • Jungwoo Yang,
  • Jin Seok Moon,
  • Jongbeom Shin,
  • Minhye Shin

摘要

Functional bowel disorders (FBDs) are characterized by chronic abdominal discomfort, altered bowel habits, and bloating, impairing quality of life. Current treatments, including dietary interventions and laxatives, have limited effectiveness and raise safety concerns. Although probiotic-based interventions have gained attention, their mechanisms remain poorly understood. This randomized, double-blind, placebo-controlled pilot trial tested the heat-treated postbiotic Lacticaseibacillus rhamnosus IDCC 3201 (RHT) over an 8-week period in patients with FBDs (RHT, n = 19; placebo, n = 15). Outcomes were measured using the IBS Symptom Severity Scale (IBS-SSS) and IBS Quality of Life (IBS-QOL) questionnaire. Results suggested that the RHT group showed reductions in IBS-SSS scores, alongside improvements in IBS-QOL and bowel activity across physical and psychosocial domains. Gut microbiota profiling revealed decreased Klebsiella pneumoniae and increased beneficial taxa, including Fusicatenibacter saccharivorans and Bacteroides caccae. Metabolomics analysis revealed progressive alterations in the RHT group, with clear distinction from baseline by week 8. Amino acid metabolism-related metabolites increased, whereas inflammation-associated eicosanoids decreased. These findings suggest that RHT alleviates FBD symptoms and improves quality of life by modulating gut microbiota and fecal metabolome, supporting its potential as a postbiotic-based therapeutic strategy.